Latest Breaking News On - திசு ரேகேனீக்ஷ குழு ப்ல் - Page 1 : comparemela.com

8 February 2021 | 08:05am StockMarketWire.com - Regenerative medical devices company Tissue Regenix said it expected its annual revenue to slip 2%, in what it described as a strong performance against a challenging Covid-19 backdrop. Revenue or the year through December was expected to fall to £12.8 million, down from £13.0 million year-on-year. We were successful in maintaining a sales line consistent with previous years and additionally securing further strategic partners and private label agreements in an industry where many companies experienced a downturn in demand as hospital resources were redirected, chief executive Daniel Lee said. With two new products launched during the year and the commencement of our capacity expansion programme following the fundraise completed in June 2020, the group is well positioned to address market demand and new opportunities as market conditions normalise.

Daniel leeTissue regenix groupTissue regenixTissue regenix group plcLon trxTrx lடேனியல் லீதிசு ரேகேனீக்ஷ குழுதிசு ரேகேனீக்ஷதிசு ரேகேனீக்ஷ குழு ப்ல்லோன் த்ர்க்ஷத்ர்க்ஷ ல்